ACADIA Pharmaceuticals (FRA:DR6) Days Sales Outstanding : 38.78 (As of Mar. 2025)

View and export this data going back to 2004. Start your Free Trial

What is ACADIA Pharmaceuticals Days Sales Outstanding?

ACADIA Pharmaceuticals's average Accounts Receivable for the three months ended in Mar. 2025 was €96.1 Mil. ACADIA Pharmaceuticals's Revenue for the three months ended in Mar. 2025 was €226.0 Mil. Hence, ACADIA Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2025 was 38.78.

The historical rank and industry rank for ACADIA Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:

FRA:DR6' s Days Sales Outstanding Range Over the Past 10 Years
Min: 33.3 Med: 37.54 Max: 124.32
Current: 36.72

During the past 13 years, ACADIA Pharmaceuticals's highest Days Sales Outstanding was 124.32. The lowest was 33.30. And the median was 37.54.

FRA:DR6's Days Sales Outstanding is ranked better than
79.5% of 844 companies
in the Biotechnology industry
Industry Median: 70.135 vs FRA:DR6: 36.72

ACADIA Pharmaceuticals's Days Sales Outstanding declined from Mar. 2024 (42.70) to Mar. 2025 (38.78).

ACADIA Pharmaceuticals Days Sales Outstanding Historical Data

The historical data trend for ACADIA Pharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACADIA Pharmaceuticals Days Sales Outstanding Chart

ACADIA Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Sales Outstanding

Get a 7-Day Free Trial

36.12

41.16

43.24

40.77

36.79

ACADIA Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Days Sales Outstanding	Get a 7-Day Free Trial															42.70	37.24	37.38	33.64	38.78

Competitive Comparison of ACADIA Pharmaceuticals's Days Sales Outstanding

For the Biotechnology subindustry, ACADIA Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ACADIA Pharmaceuticals's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's Days Sales Outstanding falls into.

Save Embed

;

Save Embed

;

ACADIA Pharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

ACADIA Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2024 is calculated as

	Days Sales Outstanding (A: Dec. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )	/	Revenue (A: Dec. 2024 )	*	Days in Period
=	( (90.111	+	94.296)	/	2 )	/	914.696	*	365
=	92.2035					/	914.696	*	365
=	36.79

ACADIA Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding (Q: Mar. 2025 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2024 )	+	Accounts Receivable (A: Mar. 2025 ))	/	count )	/	Revenue (A: Mar. 2025 )	*	Days in Period
=	( (94.296	+	97.812)	/	2 )	/	225.993	*	365 / 4
=	96.054					/	225.993	*	365 / 4
=	38.78

ACADIA Pharmaceuticals (FRA:DR6) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

ACADIA Pharmaceuticals Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

ACADIA Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (FRA:DR6) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

ACAD:USA DR6:Germany

Address

12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130

Website

https://www.acadia.com

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

ACADIA Pharmaceuticals Headlines

No Headlines